Table 1.

Baseline characteristics of patients undergoing allogeneic hematopoietic stem cell transplantation

HBsAg+
HBsAg-
P
No. patients   82   721   
Age, y (range)   35 (20-54)   32 (18-67)   .104  
Sex, no. male/no. female   57/25   408/313   .025  
Primary disease, no.    .472  
AML   30   222   
CML   22   187   
Lymphoma   9   105   
ALL   6   100   
Myeloma   6   35   
Severe aplastic anemia   5   26   
CLL   2   18   
Myelofibrosis   2   14   
Other*  0   14   
Anti-HBc+ and anti-HBs+, no.   0   239   
Anti-HBs+, anti-HBc-, no.   0   182   
Donor type, no.    .160  
HLA-identical sibling   61   481   
Unrelated   21   240   
Conditioning regimen, no.    .975  
TBI containing   37   324   
Cyclophosphamide plus other drug   33   294   
Other drugs   4   30   
Non-TBI containing   45   397   
Cyclophosphamide alone   9   26   
Busulfan and cyclophosphamide   35   314   
Other   1   57   
GVHD prophylaxis, no.    .999  
Cyclosporine with or without other drugs   80   702   
Other drugs   2   19   
Alanine aminotransaminase, U/L (range)†  30 (9-61)   27 (10-63)   .895  
Bilirubin, μM (range)‡
 		 12 (2-20)
 		 10 (3-18)
 		 .786
 
HBsAg+
HBsAg-
P
No. patients   82   721   
Age, y (range)   35 (20-54)   32 (18-67)   .104  
Sex, no. male/no. female   57/25   408/313   .025  
Primary disease, no.    .472  
AML   30   222   
CML   22   187   
Lymphoma   9   105   
ALL   6   100   
Myeloma   6   35   
Severe aplastic anemia   5   26   
CLL   2   18   
Myelofibrosis   2   14   
Other*  0   14   
Anti-HBc+ and anti-HBs+, no.   0   239   
Anti-HBs+, anti-HBc-, no.   0   182   
Donor type, no.    .160  
HLA-identical sibling   61   481   
Unrelated   21   240   
Conditioning regimen, no.    .975  
TBI containing   37   324   
Cyclophosphamide plus other drug   33   294   
Other drugs   4   30   
Non-TBI containing   45   397   
Cyclophosphamide alone   9   26   
Busulfan and cyclophosphamide   35   314   
Other   1   57   
GVHD prophylaxis, no.    .999  
Cyclosporine with or without other drugs   80   702   
Other drugs   2   19   
Alanine aminotransaminase, U/L (range)†  30 (9-61)   27 (10-63)   .895  
Bilirubin, μM (range)‡
 		 12 (2-20)
 		 10 (3-18)
 		 .786
 

AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; TBI, total body irradiation; GVHD, graft-versus-host disease; and HLA, human leukocyte antigen.

*

Thalassemia, carcinoma of breast.

†

Normal range, 6-53 U/L.

‡

Normal range, 7-19 μM.

View Large